×
Join our live online event
How top hedge funds use news to make money
form the stock market & how ordinary people are
copying their strategies
Register now!
form the stock market & how ordinary people are
copying their strategies
No thanks
LYEL – lyell immunopharma, inc. (US:NASDAQ)
DELAYED
$
| Volume Shares | |
| 1 Day Range | |
| Volume Ratio | |
| 52 Week High | |
| 52 Week Low |
| VWAP | |
| Today’s Volatility | |
| 20 Days Volatility | |
| Open | |
| Prior Close |
1D
5D
1M
3M
YTD
1Y
3Y
1 Day
LYEL
SPY
QQQ
Swipe to see more
Main News & Impact Reports
Date
Time
Symbol
Headline
Impact
11/24
07:19 am
lyel
Lyell Immunopharma (NASDAQ:LYEL) had its "neutral" rating reaffirmed by analysts at HC Wainwright.
High
Report
Lyell Immunopharma (NASDAQ:LYEL) had its "neutral" rating reaffirmed by analysts at HC Wainwright.
11/13
12:38 pm
lyel
Lyell Immunopharma reports Q3 results [Seeking Alpha]
Low
Report
Lyell Immunopharma reports Q3 results [Seeking Alpha]
11/12
04:32 pm
lyel
Lyell Immunopharma Reports Business Highlights and Financial Results for the Third Quarter 2025 [Yahoo! Finance]
Low
Report
Lyell Immunopharma Reports Business Highlights and Financial Results for the Third Quarter 2025 [Yahoo! Finance]
11/12
04:05 pm
lyel
Lyell Immunopharma Reports Business Highlights and Financial Results for the Third Quarter 2025
Medium
Report
Lyell Immunopharma Reports Business Highlights and Financial Results for the Third Quarter 2025
11/11
07:08 pm
lyel
Lyell acquires worldwide rights from ICT to CAR T-cell therapy [Yahoo! Finance]
Low
Report
Lyell acquires worldwide rights from ICT to CAR T-cell therapy [Yahoo! Finance]
11/10
07:41 am
lyel
Lyell Immunopharma Acquires Exclusive Global Rights to a Next-Generation CAR T-Cell Product Candidate in Clinical Development for Metastatic Colorectal Cancer [Yahoo! Finance]
Low
Report
Lyell Immunopharma Acquires Exclusive Global Rights to a Next-Generation CAR T-Cell Product Candidate in Clinical Development for Metastatic Colorectal Cancer [Yahoo! Finance]
11/10
07:30 am
lyel
Lyell Immunopharma Acquires Exclusive Global Rights to a Next-Generation CAR T-Cell Product Candidate in Clinical Development for Metastatic Colorectal Cancer
Low
Report
Lyell Immunopharma Acquires Exclusive Global Rights to a Next-Generation CAR T-Cell Product Candidate in Clinical Development for Metastatic Colorectal Cancer
11/3
09:00 am
lyel
Lyell Announces Two Oral Presentations from the Phase 1/2 Clinical Trial of Ronde-Cel for the Treatment of Aggressive Large B-Cell Lymphoma at the 67th ASH Annual Meeting and Exposition
Low
Report
Lyell Announces Two Oral Presentations from the Phase 1/2 Clinical Trial of Ronde-Cel for the Treatment of Aggressive Large B-Cell Lymphoma at the 67th ASH Annual Meeting and Exposition
Date
Time
Symbol
Company Name
Action
%Chg
Date
Time
Action
From
To
Firm
Impact
%Chg
Date
Time
Symbol
Headline
Impact
11/14
04:34 pm
lyel
Form SCHEDULE 13G/A Lyell Immunopharma, Inc. Filed by: ARCH Venture Fund IX, L.P.
Low
Report
Form SCHEDULE 13G/A Lyell Immunopharma, Inc. Filed by: ARCH Venture Fund IX, L.P.
11/14
04:08 pm
lyel
Form SCHEDULE 13G/A Lyell Immunopharma, Inc. Filed by: Foresite Capital Fund IV, L.P.
Low
Report
Form SCHEDULE 13G/A Lyell Immunopharma, Inc. Filed by: Foresite Capital Fund IV, L.P.
11/12
08:37 pm
lyel
Form 4 Lyell Immunopharma, Inc. For: Nov 10 Filed by: Seely Lynn
Low
Report
Form 4 Lyell Immunopharma, Inc. For: Nov 10 Filed by: Seely Lynn
11/12
08:35 pm
lyel
Form 4 Lyell Immunopharma, Inc. For: Nov 10 Filed by: Bulis Veronica Sanchez
Low
Report
Form 4 Lyell Immunopharma, Inc. For: Nov 10 Filed by: Bulis Veronica Sanchez
11/12
08:33 pm
lyel
Form 4 Lyell Immunopharma, Inc. For: Nov 10 Filed by: Lee Gary K.
Low
Report
Form 4 Lyell Immunopharma, Inc. For: Nov 10 Filed by: Lee Gary K.
11/12
08:32 pm
lyel
Form 4 Lyell Immunopharma, Inc. For: Nov 10 Filed by: Hill Stephen J.
Low
Report
Form 4 Lyell Immunopharma, Inc. For: Nov 10 Filed by: Hill Stephen J.
11/12
04:57 pm
lyel
Form SCHEDULE 13G/A Lyell Immunopharma, Inc. Filed by: NEWTON (PTC) Ltd
Low
Report
Form SCHEDULE 13G/A Lyell Immunopharma, Inc. Filed by: NEWTON (PTC) Ltd
11/12
04:20 pm
lyel
Form 10-Q Lyell Immunopharma, Inc. For: Sep 30
Medium
Report
Form 10-Q Lyell Immunopharma, Inc. For: Sep 30
Stock Stats
| News Stats | |
|---|---|
| All News | |
| News Wires | |
| Media Monitoring | |
| SEC Edgar Filings | |
| Upgrades | |
| Downgrades | |
| Initiated | |
| Reiterated | |
| Last Earnings | |
| Last Earnings EPS | |
| Next Earnings | |
| Order Stats |
|---|
| Sub-Penny |
|
|
| Odd lot |
|
|
| Avg. bid-ask spread |
|
|
| Avg. bid-ask size |
|
|
| Shares at ask/bid |
|
|
| Off exchange |
|
|
Main News & Impact Reports
TOP News Gainers
TOP News Decliners
Don’t Miss Out On The Next BIG Stock Move
Never get left behind with our daily ‘Shakers & Movers’ newsletter. Discover the biggest gainer or loser in the stock market, and learn exactly WHY it moved. To find out which one caught Wall Street by surprise TODAY, sign up to our newsletter below: